(Q35842644)

10 August 2017

1 reference

title

Controlled-release and local delivery of therapeutic antibodies (English)

1 reference

10 August 2017

David W Grainger

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

1029-1044

1 reference

Fc receptors and their interactions with immunoglobulins

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Engineering antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Generation and production of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

IgA antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Recombinant secretory immunoglobulin A in passive immunotherapy: linking immunology and biotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Recombinant immunoglobulin A: powerful tools for fundamental and applied research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Efficient purification of mouse anti-FGF receptor IgM monoclonal antibody by magnetic beads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Kinetic and affinity limits on antibodies produced during immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Fc receptors are required in passive and active immunity to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

PEGylated antibodies and antibody fragments for improved therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Prolonged in vivo residence times of antibody fragments associated with albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Retargeting serum immunoglobulin with bispecific diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Systemic and topical immunoglobulin treatment in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Antibody-based therapies for emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Recombinant immunotoxins in targeted cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Monoclonal antibodies as therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Intracellular antibodies and challenges facing their use as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Antibodies produced in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Plant antibodies for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Polymers for the sustained release of proteins and other macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Macromolecules released from polymers: diffusion into unstirred fluids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

A tunable hydrogel for encapsulation and controlled release of bioactive proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Penetration of engineered antibody fragments into the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Polymeric controlled delivery for immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

A novel spinal implant infection model in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Surgical irrigation with pooled human immunoglobulin G to reduce post-operative spinal implant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Formatting antibody fragments to mediate specific therapeutic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Synthetic Human Antibodies: Selecting and Evolving Functional Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Building drug delivery into tissue engineering design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1029

10.1517/14712598.4.7.1029

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference